Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29576132 | 0.81 | HTR7 (0.43) | GRM4MBOAT4PDE10AHCRTR1HCRTR2 | |
| SCHEMBL31043116 | 0.81 | MAPT (0.37) | GRM4MAPT | |
| SCHEMBL17239464 | 0.81 | HTR7 (0.43) | GRM4MBOAT4PDE10AHCRTR1HCRTR2 | |
| SCHEMBL22758369 | 0.81 | MAPT (0.37) | GRM4MAPT | |
| SCHEMBL17801501 | 0.77 | MBOAT4 (0.35) | MBOAT4PDE10AHCRTR1HCRTR2 | |
| SCHEMBL12093565 | 0.77 | KDR (0.42) | GRIN1GRIN2BMBOAT4PDE10AHCRTR1 | |
| SCHEMBL15607558 | 0.77 | MBOAT4 (0.41) | GRM4MBOAT4PDE10AHCRTR1HCRTR2 | |
| SCHEMBL15832227 | 0.77 | CCR1 (0.43) | GRM4RXRAGRIN1GRIN2BMBOAT4 | |
| SCHEMBL30052574 | 0.77 | MBOAT4 (0.41) | GRM4MBOAT4PDE10AHCRTR1HCRTR2 | |
| SCHEMBL363302 | 0.77 | CYP3A4 (0.38) | GRM4RXRAGRIN1GRIN2BMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| WO-2016031842-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING EFFECT | 塩野義製薬株式会社 | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | PRKAA1, PRKAA2, PRKAG1 | GRM4 2255/4885RXRA 893/4885GRIN1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.